洛斯公司(L)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

L 洛斯公司

盘前交易 02-06 08:16:45 EST

110.89

+1.46

+1.33%

最高111.61	最低109.77	成交量87.47万
今开109.77	昨收109.43	日振幅1.69%
总市值229.16亿	流通市值188.68亿	总股本2.07亿
成交额9,702万	换手率0.51%	流通股本1.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"L","market":"US","secType":"STK","nameCN":"洛斯公司","latestPrice":110.89,"timestamp":1770325200000,"preClose":109.43,"halted":0,"volume":874664,"delay":0,"changeRate":0.013341862377775689,"floatShares":170151602,"shares":206659567,"eps":6.85547,"marketStatus":"盘前交易","change":1.46,"latestTime":"02-06 08:16:45 EST","open":109.77,"high":111.61,"low":109.765,"amount":97024728.192,"amplitude":0.01686,"askPrice":118,"askSize":50,"bidPrice":107.4,"bidSize":9,"shortable":3,"etf":0,"ttmEps":6.85547,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770388200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":-341002800000,"exchange":"NYSE","adjPreClose":110.89,"dividendRate":0.002254,"postHourTrading":{"tag":"盘后","latestPrice":110.9,"preClose":110.89,"latestTime":"19:51 EST","volume":82111,"amount":9105314.81,"timestamp":1770339081471,"change":0.01,"changeRate":0.00009,"amplitude":0.000721},"volumeRatio":1.0975922251454953,"impliedVol":0.1553,"impliedVolPercentile":0.112},"requestUrl":"/m/hq/s/L/tweets","defaultTab":"tweets","newsList":[{"id":"1132811598","title":"Pyxis Oncology宣布临时CEO任命及领导层交接，聚焦战略重点与项目延续性","url":"https://stock-news.laohu8.com/highlight/detail?id=1132811598","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132811598?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:49","pubTimestamp":1770119377,"startTime":"0","endTime":"0","summary":"波士顿，2026年2月3日——临床阶段生物制药公司Pyxis Oncology, Inc.今日宣布领导层交接计划，旨在持续推进公司战略与临床目标的执行。自公司首次公开募股以来一直担任董事会成员的Thomas Civik被任命为临时首席执行官，即刻生效。通过此次人事调整，Pyxis Oncology将由深度熟悉公司战略及研发项目的资深领导者掌舵。董事会主席John Flavin表示：\"任命Tom为临时CEO是为了确保领导力的稳健过渡与业务连续性。Pyxis Oncology已奠定坚实的科研与临床基础，我们对核心项目的前景保持乐观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4139","PYXS","R","BK4585","LU0053666078.USD","BK4588","LU0210528500.USD","ADC","BK4231","BK4107","BK4232","BK4022","LU2487616109.SGD","L"],"gpt_icon":0},{"id":"2601793498","title":"超20亿美元交易官宣终止，宜明昂科：对下一步BD充满信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2601793498","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601793498?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:39","pubTimestamp":1767778775,"startTime":"0","endTime":"0","summary":"“坦率讲，我个人对目前把全球权益拿回来是感到非常高兴的。”在1月7日早上的电话会上，宜明昂科生物医药技术（上海）股份有限公司（宜明昂科，1541.HK）创始人、董事长田文志表达了上述感受。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601073611555858.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611555858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0053666078.USD","LU2487616109.SGD","L","BK4585","BK4588","LU0210528500.USD","BK4107"],"gpt_icon":0},{"id":"2600089095","title":"达伯舒新适应症医保落地 系晚期pMMR子宫内膜癌唯一医保抗PD-(L)1药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2600089095","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600089095?lang=zh_cn&edition=full","pubTime":"2026-01-01 15:16","pubTimestamp":1767251765,"startTime":"0","endTime":"0","summary":"中国网财经1月1日讯今日，北京、上海、苏州、郑州等多地医院开出信迪利单抗注射液(达伯舒)新增子宫内膜癌适应症医保处方，标志着该适应症在被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》后正式落地执行医保价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601013607458241.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601013607458241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4107","BK4588","LU2487616109.SGD","LU1169590202.USD","L","LU1169589451.USD","PD","LU0053666078.USD","BK4023","BK4585","LU0210528500.USD"],"gpt_icon":0},{"id":"1123923184","title":"洛斯公司 - 最高法院发现与基础合伙协议相关的违约行为，发回审理侵权干扰问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1123923184","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123923184?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457296,"startTime":"0","endTime":"0","summary":"洛斯公司 - 最高法院发现与基础合伙协议相关的违约行为，发回审理侵权干扰问题","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4588","BK4107","LU0210528500.USD","LU2487616109.SGD","BK4585","L"],"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590394122?lang=zh_cn&edition=full","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z4B17.USD","LU0963586101.USD","BK4006","BK4588","BK4080","LU0210528500.USD","LU2065731478.USD","BK4585","BK4107","BK4231","IE0031619046.USD","ORR","BK4187","CRS","LU2487616109.SGD","IE00B7SZL793.SGD","L","ADC","LU0053666078.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2586225792","title":"三生制药：707联合化疗的临床2期数据公布 即将开展两项关键3期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2586225792","media":"国信证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586225792?lang=zh_cn&edition=full","pubTime":"2025-11-27 07:57","pubTimestamp":1764201420,"startTime":"0","endTime":"0","summary":"近日，三生制药在2025 年STIC 会议上以LBA 方式发布707 联合化疗在一线NSCLC 的临床2 期研究数据。辉瑞与三生制药达成协议后，积极推进707 的临床开发，并将707 管线列为其核心管线，目前已经提交5 个新的临床申请，在全球超过25 个城市、500 多家临床中心开展临床研究，预计到2026 年底将新增10 个适应症的临床试验，以及10 个以上的新型治疗方案。辉瑞即将在NSCLC 和CRC 适应症中开展两项临床3 期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127091749951c9fe5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127091749951c9fe5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4107","IE00BBT3K403.USD","L","SG9999003800.SGD","IE00BLSP4452.SGD","SGXZ57979304.SGD","SG9999002224.SGD","LU0868494617.USD","LU0289739699.SGD","LU1066051498.USD","IE00BLSP4239.USD","LU0225771236.USD","IE000M9KFDE8.USD","BK4550","LU1066053197.SGD","IE00B19Z3581.USD","LU1023059063.AUD","LU0053666078.USD","IE00B19Z3B42.SGD","LU0210528500.USD","LU2487616109.SGD","LU0985481810.HKD","SG9999001176.SGD","LU1057294990.SGD","LU0122379950.USD","LU0306806265.USD","LU0225284248.USD","LU0456855351.SGD","LU0058720904.USD","LU0321505439.SGD","LU0306807586.USD","BK4568","LU1894683264.USD","BK4599","LU1894683348.USD","LU0321505868.SGD","BK4007","BK4585","BK4534","BK4581","BK4588","LU1883839398.USD","SG9999013999.USD","SG9999002232.USD","IE0002270589.USD","LU0170899867.USD","SG9999011175.SGD","LU0234572021.USD","BK4533"],"gpt_icon":1},{"id":"1159433604","title":"CNA金融第三季度调整后每股收益为1.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159433604","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159433604?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:28","pubTimestamp":1763569705,"startTime":"0","endTime":"0","summary":"11月3日 - CNA金融第三季度每股收益为1.48美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU0210528500.USD","BK4588","L","LU2487616109.SGD","CNA","BK4585","BK4107"],"gpt_icon":0},{"id":"1125354250","title":"洛斯公司选举迪诺·罗布斯托为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1125354250","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125354250?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:27","pubTimestamp":1763569679,"startTime":"0","endTime":"0","summary":"11月3日 - 洛斯公司（Loews）宣布，迪诺·罗布斯托（Dino Robusto）被选为其董事会成员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","BK4107","BK4585","LU0053666078.USD","L","LU2487616109.SGD","BK4588"],"gpt_icon":0},{"id":"2583584449","title":"新股消息 | 明基医院更新招股书 为华东地区最大的民营营利性综合医院集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2583584449","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583584449?lang=zh_cn&edition=full","pubTime":"2025-11-13 07:32","pubTimestamp":1762990322,"startTime":"0","endTime":"0","summary":"招股书显示，明基医院是中国内地的一家民营营利性综合医院集团，目前该公司拥有和运营南京明基医院和苏州明基医院等两家民营营利性综合医院。根据弗若斯特沙利文的数据，以2024年总收入计，南京明基医院是中国第三大民营营利性综合医院，亦是江苏省最大的民营营利性综合医院。苏州明基医院2013年开始运营，为三级综合性医院。明基医院专注于通过公司的多学科民营营利性综合医院为患者提供连续的优质医疗服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2487616109.SGD","BK4107","LU0211331839.USD","IE00B3T34201.USD","LU1978683503.SGD","BK1209","IE00BZ9MQY76.HKD","09906","LU0320765489.SGD","LU0312595415.SGD","02581","BK4580","LU1989764664.SGD","LU1989764748.USD","BK4504","LU1854103824.USD","BK4585","LU1854104046.USD","L","JCI","BK4588","LU0210528500.USD","LU0124384867.USD","LU0070302665.USD","IE00B894F039.SGD","LU0154236417.USD","LU0053666078.USD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4086","LU0208291251.USD"],"gpt_icon":0},{"id":"2582034364","title":"药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2582034364","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582034364?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:29","pubTimestamp":1762918190,"startTime":"0","endTime":"0","summary":"【药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响】凭借在肺癌领域的突出表现，默沙东的PD-1单抗K药连续在2023年、2024年成为全球药王，年销售额均突破200亿美元。谁能成为肺癌领域下一代免疫“新王”，一场争夺赛在药企中已打响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511123562061651.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511123562061651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348767384.USD","BK1161","LU2476274720.SGD","IE00BPRC5H50.USD","L","LU0348766576.USD","LU0348825331.USD","LU0502904849.HKD","BK1589","LU0348783233.USD","LU0417516738.SGD","LU1794554557.SGD","LU2097828557.USD","LU2476274308.USD","LU2778985437.USD","LU2097828805.USD","LU0417516571.SGD","ORR","LU2242644610.SGD","LU0053666078.USD","BK1583","BK4588","02696","LU0348784397.USD","LU2328871848.SGD","LU2399975544.HKD","BK1574","LU1969619763.USD","LU0210528500.USD","LU2097828631.EUR","LU0634319403.HKD","01801","LU0455707207.USD","LU2488822045.USD","LU0348827113.USD","LU2097828474.EUR","LU0417516902.SGD","LU1720050803.USD","HK0000165453.HKD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK4107","LU1961090484.USD","BK4585","LU0561508036.HKD","LU2487616109.SGD","LU2097828714.EUR","LU0540923850.HKD","09926","LU0348735423.USD"],"gpt_icon":0},{"id":"1149794522","title":"CNA金融2023年第三季度调整后每股收益为1.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149794522","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149794522?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:15","pubTimestamp":1762168530,"startTime":"0","endTime":"0","summary":"11月3日 - CNA金融第三季度每股收益为1.48美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LU0053666078.USD","BK4107","LU2487616109.SGD","CNA","LU0210528500.USD","L"],"gpt_icon":0},{"id":"2577367573","title":"PD-(L)1/VEGF赛道攻坚，依沃西冲击首个海外适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2577367573","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577367573?lang=zh_cn&edition=full","pubTime":"2025-10-22 11:58","pubTimestamp":1761105514,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明当地时间10月20日，SummitTherapeutics（纳斯达克股票代码：SMMT）在2025年三季度财报中宣布，将于2025年第四季度向美国食品药品监督管理局（FDA）提交依沃西单抗联合化疗的生物制品许可申请（BLA），用于治疗经第三代EGFR-TKI治疗进展的EGFR突变非鳞状非小细胞肺癌（NSCLC）患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510223540978275.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510223540978275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4585","LU2487616109.SGD","LU0053666078.USD","PD","LU0210528500.USD","LU1169590202.USD","BK4107","LU1169589451.USD","L","BK4023"],"gpt_icon":0},{"id":"2565513279","title":"Caleres, Inc.盘中异动 早盘急速上涨5.13%报14.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565513279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565513279?lang=zh_cn&edition=full","pubTime":"2025-09-05 21:57","pubTimestamp":1757080679,"startTime":"0","endTime":"0","summary":"北京时间2025年09月05日21时57分，Caleres, Inc.股票出现异动，股价急速拉升5.13%。Caleres, Inc.股票所在的服装零售行业中，整体跌幅为0.86%。其相关个股中，Zumiez Inc.、Caleres, Inc.、J. Jill, Inc.涨幅较大，露露乐蒙、707 Cayman Holdings Limited、Duluth Holdings Inc.较为活跃，换手率分别为11.86%、6.29%、4.45%，振幅较大的相关个股有Duluth Holdings Inc.、707 Cayman Holdings Limited、Zumiez Inc.，振幅分别为16.71%、11.83%、10.79%。消息层面，截至21时57分，《KeyBanc维持Caleres持有评级》资讯为影响Caleres, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905215800977a6599&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905215800977a6599&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4107","LU2487616109.SGD","BK4585","L","LU0210528500.USD","LU0053666078.USD"],"gpt_icon":0},{"id":"1123770804","title":"博通Q3 AI芯片收入超预期增63%，神秘新客户下单百亿，料下财年AI前景“大幅”改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1123770804","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123770804?lang=zh_cn&edition=full","pubTime":"2025-09-05 06:52","pubTimestamp":1757026373,"startTime":"0","endTime":"0","summary":"陈福阳称，博通正在与潜在客户合作开发AI加速器。陈福阳称，三季度博通的AI半导体营收同比增长63%至52亿美元，这也高于分析师预期的51.1亿美元。博通第二财季的AI芯片业务收入同比增长46%。陈福阳称，博通预计，四季度AI半导体营收增至62亿美元。博通2024财年的总营收将近516亿美元。博通2023年以610亿美元收购VMware，该业务现已成为其基础设施软件部门的核心，占前一财季销售额的44%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/05ac5664b8d2d8af314c2fe1951c78e0","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/05ac5664b8d2d8af314c2fe1951c78e0"],"rights":{"source":"lsy1700700604709","url":"https://wallstreetcn.com/articles/3754969","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"37d92a7d0c4ca95ac9f2b896894d597f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3754969","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"博通Q3 AI芯片收入超预期增63%，神秘新客户下单百亿，料下财年AI前景“大幅”改善","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1700700604709","symbols":["IE0034235303.USD","IE00BWXC8680.SGD","LU0011850046.USD","IE0004445015.USD","IE00BKVL7J92.USD","IE00BMPRXR70.SGD","BK4598","BK4588","IE00BMPRXN33.USD","L","IE00BLSP4239.USD","IE00BDGV0183.EUR","IE00BYV24P56.USD","IE00BMCWC346.EUR","IE00BVYPNV92.GBP","BK4575","LU0006306889.USD","BK4551","AVGO","BK4612"],"gpt_icon":1},{"id":"2563001827","title":"克雷克电业盘中异动 股价大涨5.64%报12.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2563001827","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563001827?lang=zh_cn&edition=full","pubTime":"2025-08-29 00:31","pubTimestamp":1756398692,"startTime":"0","endTime":"0","summary":"北京时间2025年08月29日00时31分，克雷克电业股票出现波动，股价快速上涨5.64%。截至发稿，该股报12.92美元/股，成交量1.4245万股，换手率0.02%，振幅5.56%。克雷克电业股票所在的黄金行业中，整体跌幅为0.06%。克雷克电业公司简介：Collective Mining Ltd是一家勘探和开发公司，专注于在南美洲识别和勘探有前景的矿产项目。该公司负责发现、许可和建造哥伦比亚的金矿。Guayabales项目的钻井工作正在进行中，该项目与Marmato矿床相邻，具有战略意义，初步分析结果正在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829003132a701f98f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829003132a701f98f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2487616109.SGD","L","BK4107","LU0053666078.USD","LU0210528500.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2563329011","title":"康方生物：HARMONI-A最终分析达到OS临床终点 公司国际化全面加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2563329011","media":"方正证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563329011?lang=zh_cn&edition=full","pubTime":"2025-08-29 00:00","pubTimestamp":1756396800,"startTime":"0","endTime":"0","summary":"2）依沃西首个适应症为EGFR-TKI 耐药二线非鳞状NSCLC，于2024 年5 月获批，并纳入医保。3）2025 年4 月，依沃西联合化疗对比替雷利珠联合化疗一线sqNSCLC 的III 期临床试验达到PFS 主要终点，具有统计学显著意义和重大临床获益。2025 年7 月，NMPA 已受理该适应症的sNDA。SUMMIT 于2025 年5 月宣布HARMONi 达到PFS 主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829150132a4a6fa6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829150132a4a6fa6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0210528500.USD","LU0053666078.USD","L","BK4588","BK4107","LU2487616109.SGD","BK4585","09926"],"gpt_icon":0},{"id":"2563010900","title":"Nexalin Technology, Inc.盘中异动 快速拉升6.46%报0.857美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2563010900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563010900?lang=zh_cn&edition=full","pubTime":"2025-08-28 22:01","pubTimestamp":1756389687,"startTime":"0","endTime":"0","summary":"北京时间2025年08月28日22时01分，Nexalin Technology, Inc.股票出现波动，股价大幅上涨6.46%。Nexalin Technology, Inc.股票所在的医疗器械行业中，整体跌幅为0.70%。其相关个股中，Icecure Medical Ltd.、Aethlon Medical, Inc.、飞天兆业涨幅较大，Icecure Medical Ltd.、Aethlon Medical, Inc.、Strata Skin Sciences, Inc.较为活跃，换手率分别为15.25%、9.75%、6.15%，振幅较大的相关个股有Icecure Medical Ltd.、Strata Skin Sciences, Inc.、Aethlon Medical, Inc.，振幅分别为16.24%、15.24%、14.47%。Nexalin Technology, Inc.公司简介：Nexalin Technology Inc设计和开发创新的神经刺激产品，独特且有效地帮助对抗正在进行的全球精神健康流行病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082822012797676b15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082822012797676b15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053666078.USD","BK4107","LU2487616109.SGD","BK4588","NXL","BK4082","BK4585","L","LU0210528500.USD"],"gpt_icon":0},{"id":"2562701704","title":"“大牛股”康方生物，核心产品大卖亏损却扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2562701704","media":"时代财经APP","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562701704?lang=zh_cn&edition=full","pubTime":"2025-08-28 12:12","pubTimestamp":1756354374,"startTime":"0","endTime":"0","summary":"财报数据显示，今年上半年，康方生物总收入为14.12亿元，同比增长37.75%。在商业授权收入方面，康方生物在今年上半年已收到990万元。不过，截至今年上半年，康方生物仍处于亏损状态，且亏损金额进一步扩大，为5.88亿元，这一数字在去年同期为亏损2.49亿元。投资者更为关注的是，康方生物核心产品的研发和商业化销售情况，尤其是依沃西在全球市场头对头试验进展。上述相关负责人表示，今年上半年，康方生物在中国市场医院覆盖进一步深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828125215a4a424fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828125215a4a424fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4516","LU1934455863.HKD","BK4007","IE00BBT3K403.USD","LU0211331839.USD","LU1093756325.SGD","ALK","LU1585245621.USD","LU1116320737.USD","LU2487616109.SGD","SG9999014575.USD","IE00BJT1NW94.SGD","LU0070302665.USD","IE00BN8TJ469.HKD","LU1941712264.USD","LU1023059063.AUD","LU2023250843.SGD","IE00BSNM7G36.USD","LU2023250504.SGD","LU0058720904.USD","BK4008","LU1929549753.HKD","LU0965509010.AUD","LU1035773651.USD","LU0203347892.USD","LU1057294990.SGD","SGXZ57979304.SGD","LU0208291251.USD","BK4585","LU0106261372.USD","SG9999014542.SGD","LU2468319806.SGD","SG9999013999.USD","BK4107","IE000M9KFDE8.USD","LU1037948541.HKD","LU1934455277.USD","L","LU2324357040.USD","SG9999001440.SGD","LU1061106388.HKD","MRK","OS","BK4534","SG9999015341.SGD","LU1066051225.USD","LU2106854487.HKD","LU1989772923.USD","SG9999001176.SGD","LU1974910355.USD"],"gpt_icon":0},{"id":"2562771495","title":"Northann Corp.盘中异动 临近收盘股价大跌5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562771495","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562771495?lang=zh_cn&edition=full","pubTime":"2025-08-28 04:15","pubTimestamp":1756325709,"startTime":"0","endTime":"0","summary":"北京时间2025年08月28日04时15分，Northann Corp.股票出现异动，股价大幅下跌5.45%。截至发稿，该股报0.135美元/股，成交量56.1708万股，换手率0.59%，振幅7.06%。Northann Corp.股票所在的家具家电行业中，整体涨幅为0.02%。Northann Corp.公司简介：Northann Corp 专注于其旗舰品牌 “Benchwick” 的 3D 打印地板解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082804150997658db9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082804150997658db9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4107","LU0210528500.USD","BK4585","BK4588","LU0053666078.USD","BK4086","L","LU2487616109.SGD","NCL"],"gpt_icon":0},{"id":"2560133542","title":"患者死亡！AI制药第一股也拿不下CD47","url":"https://stock-news.laohu8.com/highlight/detail?id=2560133542","media":"药时代","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560133542?lang=zh_cn&edition=full","pubTime":"2025-08-18 17:03","pubTimestamp":1755507802,"startTime":"0","endTime":"0","summary":"2020年，通过这场价值不菲的收购，吉利德踌躇满志地入局CD47 ，跻身CD47领域头部玩家。ALX的核心管线为evorpacept，也是一款CD47抑制剂。ALX的CD47项目也毫无意外的不顺利。2023年8月，ALX宣布将终止evorpacept的ASPEN-02和ASPEN-05研究，这两项研究分别用于评估evorpacept与化疗药物联合治疗MDS和AML的有效性。目前，辉瑞的这两款CD47项目均已暂停。前文提到，CD47在许多肿瘤细胞表面大量上调。但需要注意的是，CD47不仅在肿瘤细胞表面表达，同时还在人体红细胞高度表达。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818170514a6eca876&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818170514a6eca876&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4452.SGD","LU2487616109.SGD","LU0234572021.USD","LU0225284248.USD","LU0225771236.USD","SG9999002232.USD","BK4107","BK4550","LU1057294990.SGD","BK4581","LU0985481810.HKD","LU0868494617.USD","SG9999011175.SGD","LU0321505868.SGD","IE0002270589.USD","SG9999002224.SGD","LU0289739699.SGD","IE00B19Z3581.USD","PFE","LU0170899867.USD","LU1894683348.USD","BK4585","SGXZ57979304.SGD","LU0321505439.SGD","LU1883839398.USD","BK4534","SG9999003800.SGD","BK4592","L","BK4533","LU1066051498.USD","SG9999001176.SGD","IE00BLSP4239.USD","BK4588","LU0210528500.USD","LU0306807586.USD","BK4568","LU0122379950.USD","LU1066053197.SGD","SG9999013999.USD","SG9999001176.USD","IE00B19Z3B42.SGD","LU0058720904.USD","LU0306806265.USD","IE00BBT3K403.USD","LU0053666078.USD","LU1023059063.AUD","LU1894683264.USD","BK4599","BK4007"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.loews.com","stockEarnings":[{"period":"1week","weight":0.0593},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.0809},{"period":"6month","weight":0.1826},{"period":"1year","weight":0.2852},{"period":"ytd","weight":0.053}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"美国洛斯保险公司成立于1969年，是一家控股公司。其子公司从事以下业务：商业财产和意外伤害保险；天然气和天然气液体的运输和存储；以及连锁酒店的经营。","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.007002},{"month":2,"riseRate":0.565217,"avgChangeRate":0.00568},{"month":3,"riseRate":0.6,"avgChangeRate":-0.006321},{"month":4,"riseRate":0.608696,"avgChangeRate":0.006834},{"month":5,"riseRate":0.565217,"avgChangeRate":0.021104},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.001635},{"month":7,"riseRate":0.521739,"avgChangeRate":-0.001249},{"month":8,"riseRate":0.521739,"avgChangeRate":0.017827},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00607},{"month":10,"riseRate":0.673913,"avgChangeRate":0.012707},{"month":11,"riseRate":0.608696,"avgChangeRate":0.024712},{"month":12,"riseRate":0.652174,"avgChangeRate":0.020518}],"exchange":"NYSE","name":"洛斯公司","nameEN":"Loews"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"洛斯公司(L)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供洛斯公司(L)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"洛斯公司,L,洛斯公司股票,洛斯公司股票老虎,洛斯公司股票老虎国际,洛斯公司行情,洛斯公司股票行情,洛斯公司股价,洛斯公司股市,洛斯公司股票价格,洛斯公司股票交易,洛斯公司股票购买,洛斯公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"洛斯公司(L)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供洛斯公司(L)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}